Viking Therapeutics Reports Q3 2025 Results, Cash $715M, VK2735 Phase 3 Trials On Track

Viking Therapeutics, Inc.

2025-Q3 EPS reported -$1.80

Q3 2025 net loss $90.8M ($0.81/share) vs $24.9M in Q3 2024; R&D expenses rose to $90.0M from $22.8M.
Cash, equivalents and short-term investments totaled $715M as of Sept 30, 2025, down from $903M at Dec 31, 2024.
Phase 3 VANQUISH-1 for VK2735 in obesity expects enrollment completion by end of 2025; VANQUISH-2 by Q1 2026.
Phase 2 VENTURE-Oral study showed up to 12.2% mean weight loss after 13 weeks; up to 97% achieved ≥5% weight loss.
Maintenance dosing study of VK2735 initiated; plans to file IND for dual amylin/calcitonin agonist in Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.